The possible role of cerium oxide (CeO2) nanoparticles in prevention of neurobehavioral and neurochemical changes in 6-hydroxydopamine-induced parkinsonian disease

The possible role of cerium oxide (CeO2) nanoparticles in prevention of neurobehavioral and neurochemical changes in 6-hydroxydopamine-induced parkinsonian disease

Cerium oxide nanoparticles (CeO2NPs) is an efficient neuroprotective agent and showed promising effects in some neurodegenerative diseases such as Alzheimer’s disease and multiple sclerosis. However, the implication of CeO2NPs in Parkinsonism remains to be investigated. The aim of this study was to...

Full description

Bibliographic Details
Main Authors:	Maha Abd Elkader Hegazy, Hala Mohamed Maklad, Doaa A. Abd Elmonsif, Fatma Yosry Elnozhy, Malik Ahmad Alqubiea, Fisal Aliwi Alenezi, Obaid Mahdi Al abbas, Mahdi Mana Al abbas
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-12-01
Series:	Alexandria Journal of Medicine
Subjects:	Parkinson’s disease 6-OHDA CeO2NPs Oxidative stress Apoptosis Striatal dopamine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2090506816301804

Similar Items

6-hydroxydopamine and ovariectomy has no effect on heart rate variability parameters of females
by: Tomás de la Rosa, et al.
Published: (2021-10-01)

Hematological disorders in 6-hydroxydopamine-induced rat model of Parkinson’s disease
by: Lucian Hritcu
Published: (2008-09-01)

The modulatory effect of 100 Hz electroacupuncture on striatal synaptic plasticity in unilateral lesioned 6-OHDA rats
by: Min Li, et al.
Published: (2022-08-01)

PAIN IN A PARKINSON`S DISEASE RODENT ANIMAL MODEL INDUCED WITH 6-HYDROXYDOPAMINE
by: Antioch, I, et al.
Published: (2017-06-01)

Connectivity of the corticostriatal and thalamostriatal systems in normal and parkinsonian states: An update
by: Anne-Caroline Martel, et al.
Published: (2022-11-01)

Effect of 6-hydroxydopamine blockade of sympathetic nerves on systemic inflammation in an imiquimod-induced psoriasis-like mouse model
by: Siqi LIU, et al.
Published: (2022-06-01)

Effects of right-unilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: relevance for Parkinson’s disease
by: Hritcu Lucian, et al.
Published: (2008-09-01)

Ergothioneine Prevents Neuronal Cell Death Caused by the Neurotoxin 6-Hydroxydopamine
by: Saho Yuzawa, et al.
Published: (2024-01-01)

Dopamine differentiation factors produce partial motor recovery in 6-hydroxydopamine lesioned rats
by: B.K. Jin, et al.
Published: (1995-02-01)

Expression of Tgfβ1 and inflammatory markers in the 6-hydroxydopamine mouse model of Parkinson´s disease
by: Stefan Jean-Pierre Haas, et al.
Published: (2016-02-01)

Synaptic zinc contributes to motor and cognitive deficits in 6-hydroxydopamine mouse models of Parkinson's disease
by: Joanna Sikora, et al.
Published: (2020-02-01)

Pathophysiological signatures of functional connectomics in parkinsonian and dyskinetic striatal microcircuits
by: Jesús Pérez-Ortega, et al.
Published: (2016-07-01)

B Vitamins Supplement Potentiates Antiparkinsonian Effect of Flunarizine: the Behavioral and Biochemical Evidences From 6-Hydroxydopamine Animal Model
by: Mohamad Sofiabadi, et al.
Published: (2018-09-01)

Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response
by: Bárbara Mendes-Pinheiro, et al.
Published: (2021-10-01)

Longitudinal assessment of motor function following the unilateral intrastriatal 6-hydroxydopamine lesion model in mice
by: Xiuping Sun, et al.
Published: (2022-11-01)

The impact of a parkinsonian lesion on dynamic striatal dopamine transmission depends on nicotinic receptor activation
by: Katie A. Jennings, et al.
Published: (2015-10-01)

Reinforcing properties of Pramipexole in normal and parkinsonian rats
by: Michel Engeln, et al.
Published: (2013-01-01)

Evaluation of Betaine Neuroprotective Effects on 6-Hydroxydopamine-Induced hemi-Parkinsonism in Male Wistar Rats
by: Behrouz Rahmani, et al.
Published: (2019-09-01)

Growth/differentiation factor-15 deficiency compromises dopaminergic neuron survival and microglial response in the 6-hydroxydopamine mouse model of Parkinson's disease
by: Venissa Machado, et al.
Published: (2016-04-01)

The relationship between the location of a lesion in the striatal dopaminergic innervation and its behavioral manifestation in a 6-hydroxydopamine-induced model of Parkinson's disease in rats
by: Alla V. Stavrovskaya, et al.
Published: (2021-06-01)

DA-9805, a Herbal Mixture, Restores Motor Manifestations in 6-Hydroxydopamine-induced Parkinson’s Disease Mouse Model by Regulating Striatal Dopamine and Acetylcholine Levels
by: Eugene Huh, et al.
Published: (2022-06-01)

Application of a new micro-cannula for the establishment of a Parkinsonian mouse model
by: ZUO Fu-xing, YUAN Qing, CAI Hong-qing, HAN Rui-qin, WAN Jing-hai
Published: (2022-07-01)

Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson’s Disease Models
by: Ekaterina A. Yurchenko, et al.
Published: (2018-11-01)

Neuroprotective Effects of Safflower Flavonoid Extract in 6-Hydroxydopamine-Induced Model of Parkinson’s Disease May Be Related to its Anti-Inflammatory Action
by: Hui Lei, et al.
Published: (2020-11-01)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
by: Katrine Fabricius, et al.
Published: (2017-12-01)

Long-Term Motor Cortical Electrical Stimulation Ameliorates 6-Hydroxydopamine-Induced Motor Dysfunctions and Exerts Neuroprotective Effects in a Rat Model of Parkinson’s Disease
by: Chi-Wei Kuo, et al.
Published: (2022-02-01)

Propolis induces cardiac metabolism changes in 6-hydroxydopamine animal model: A dietary intervention as a potential cardioprotective approach in Parkinson’s disease
by: Valeria C. Goncalves, et al.
Published: (2022-10-01)

Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson’s disease
by: Weizhao Chen, et al.
Published: (2022-05-01)

Differential enhancement of ERK, PKA and Ca2+ signaling in direct and indirect striatal neurons of Parkinsonian mice
by: Louise-Laure Mariani, et al.
Published: (2019-10-01)

Stem cell-based regenerative medicine in Huntington’s disease: is fetal striatal grafting passing the baton? A commentary on Differentiation of pluripotent stem cells into striatal projection neurons: a pure MSN fate may not be sufficient, by Reddington AE et al. (2014). Front Cellular Neurosci 8, 398
by: Berardino ePorfirio, et al.
Published: (2015-05-01)

A comprehensive excitatory input map of the striatum reveals novel functional organization
by: Barbara J Hunnicutt, et al.
Published: (2016-11-01)

Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo
by: Dustin R. Wakeman, et al.
Published: (2017-07-01)

Exploring the 4th dimension: hippocampus, time, and memory revisited
by: Bin eYin, et al.
Published: (2011-08-01)

The Cannabigerol Derivative VCE-003.2 Exerts Therapeutic Effects in 6-Hydroxydopamine-Lesioned Mice: Comparison with The Classic Dopaminergic Replacement Therapy
by: Santiago Rodríguez-Carreiro, et al.
Published: (2023-08-01)

Striatal toe
by: Sudhir Kumar, et al.
Published: (2013-01-01)

Preventive Vitamin A Supplementation Improves Striatal Function in 6-Hydroxydopamine Hemiparkinsonian Rats
by: Anaïs Marie, et al.
Published: (2022-02-01)

Glutamatergic Tuning of Hyperactive Striatal Projection Neurons Controls the Motor Response to Dopamine Replacement in Parkinsonian Primates
by: Arun Singh, et al.
Published: (2018-01-01)

Propolis as a Potential Disease-Modifying Strategy in Parkinson’s disease: Cardioprotective and Neuroprotective Effects in the 6-OHDA Rat Model
by: Valeria C. Gonçalves, et al.
Published: (2020-05-01)

Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia
by: X. Zhou, et al.
Published: (2017-08-01)

The 6-hydroxydopamine model and parkinsonian pathophysiology: Novel findings in an older model
by: D. Hernandez-Baltazar, et al.
Published: (2017-10-01)